MiNK Therapeutics, Inc. announced its financial results for the first quarter of 2025 on May 15, 2025. The company reported a cash balance of $3.2 million at the end of the quarter.
Cash used in operations for the three months ended March 31, 2025, was $1.3 million, a decrease from $2.5 million for the same period in 2024. The net loss for the first quarter of 2025 was $2.8 million, or $0.70 per share, compared to $3.8 million, or $1.10 per share, for the first quarter of 2024.
CEO Jennifer Buell stated that the company is engaged in late-stage strategic discussions across oncology, immunology, and next-generation engineered cell therapies. These potential partnerships, along with expanded access to non-dilutive capital, are expected to unlock the full value of MiNK's technology and accelerate therapy delivery to patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.